Cardiology/Vascular Diseases | New Developments

Pluristyx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement

Lead Product(s): ESI human embryonic stem cells

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: AgeX Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction

Lead Product(s): Immune globulin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Norton Heart & Vascular Institute in Louisvill

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 28, 2020

Details:

Octapharma USA is donating Octagam® 10% and cutaquig® 16.5%, the company’s intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study. BioMatrix will be donating patient education, including instruction in subcutaneous injection.

Horizon Discovery Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic

Lead Product(s): miRNA-125b

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.

Secarna Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Lead Product(s): Antisense oligonucleotide therapies

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Lipigon

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 23, 2020

Details:

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Ncardia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of ...

Lead Product(s): Cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: BlueRock Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 21, 2020

Details:

Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

Find

Find Novel Drugs for Cardiology/Vascular Diseases under Development

Undisclosed

Product Type

Companies

Pluristyx

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement

Octapharma

Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction

Horizon Discovery Group

Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic

Secarna Pharma

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Ncardia

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of ...